Abstract:
It is currently understood that tobacco smoking is a major cause of pulmonary disease due to pulmonary/lung inflammation. However, due to a highly dynamic market place and an abundance of diverse products, less is known about the effects of e-cigarette (E-cig) use on the lung. In addition, varieties of E-cig liquids (e-liquids), which deliver nicotine and numerous flavor chemicals into the lungs, now number in the 1000s. Thus, a critical need exists for safety evaluations of these E-cig products. Herein, we employed a \"2-stage in vivo screening platform\" (zebrafish to mouse) to assess the safety profiles of e-liquids. Using the zebrafish, we collected embryo survival data after e-liquid exposure as well as neutrophil migration data, a key hallmark for a pro-inflammatory response. Our data indicate that certain e-liquids induce an inflammatory response in our zebrafish model and that e-liquid exposure alone results in pro-inflammatory lung responses in our C57BL/6J model, data collected from lung staining and ELISA analysis, respectively, in the mouse. Thus, our platform can be used as an initial assessment to ascertain the safety profiles of e-liquid using acute inflammatory responses (zebrafish, Stage 1) as our initial metric followed by chronic studies (C57BL/6J, Stage 2).
摘要:
目前了解吸烟是由肺/肺部炎症引起的肺部疾病的主要原因。然而,由于高度动态的市场和丰富多样的产品,人们对电子烟(E-CIG)对肺部的影响知之甚少。此外,各种电子烟液(电子烟液),将尼古丁和多种风味化学物质输送到肺部,现在的数字在1000。因此,对这些E-cig产品的安全性评估存在关键需求。在这里,我们使用了“2阶段体内筛选平台”(斑马鱼对小鼠)来评估电子液体的安全性。使用斑马鱼,我们收集了电子液体暴露后的胚胎存活数据以及中性粒细胞迁移数据,促炎反应的关键标志。我们的数据表明,某些电子液体在我们的斑马鱼模型中诱导炎症反应,并且在我们的C57BL/6J模型中单独的电子液体暴露导致促炎肺反应,从肺染色和ELISA分析收集的数据,分别,在老鼠身上。因此,我们的平台可以用作初步评估,以确定使用急性炎症反应的电子液体的安全性(斑马鱼,阶段1)作为我们的初始指标,随后是慢性研究(C57BL/6J,Stage2).